Nifedipine
drugOn this page
Also known as AdalatAdalat a.r.Adalat ccAdalat icAdalat la 20Adalat la 30Adalat la 60Adalat retAdalate lpAdanif xlAdipine mr 10Adipine mr 20Adipine xlAfeditab crAngiopine 10Angiopine 40 laAngiopine 5Angiopine mr 10Angiopine mr 20BAY A 1040
Summary
Nifedipine (CHEMBL193) is an approved small-molecule calcium channel blocker (ATC C08CA05) targeting GLRA1, GLRA3, and GLRB; indicated across 19 conditions including hypertensive disorder and cardiovascular disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: C08CA05 (+1 more)
- Targets: 14 (GLRA1, GLRA3, GLRB…)
- Indications: 19 conditions
- Clinical trials: 95
- Chemistry: 346.3 Da · C17H18N2O6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL193 |
| Name | Nifedipine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 4485 |
| ChEBI | CHEBI:7565 |
| ATC | C08CA05, C08CA55 |
| Molecular formula | C17H18N2O6 |
| Molecular weight | 346.3 |
| InChIKey | HYIMSNHJOBLJNT-UHFFFAOYSA-N |
SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
IUPAC name: dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Pharmacological roles (ChEBI): calcium channel blocker, vasodilator agent, tocolytic agent.
Other ChEBI roles (chemical / environmental): human metabolite.
Also known as: Adalat, Adalat a.r., Adalat cc, Adalat ic, Adalat la 20, Adalat la 30, Adalat la 60, Adalat ret, Adalate lp, Adanif xl, Adipine mr 10, Adipine mr 20
Patent coverage: 21,054 distinct patent families (74,353 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 74,026 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| GLRA1 | glycine receptor α1 subunit | Antagonist | 5.5 | 0.3% | P23415 |
| GLRA3 | glycine receptor α3 subunit | Antagonist | 4.5 | 0.2% | O75311 |
| GLRB | glycine receptor β subunit | Antagonist | 4.9 | 0.2% | P48167 |
| TRPM3 | TRPM3 | 0.1% | Q9HCF6 | ||
| CACNA1S | Cav1.1 | Antagonist | 6.3 | 0.2% | Q13698 |
| CACNA1C | Cav1.2 | Antagonist | 8.7 | 0.1% | Q13936 |
| CACNA1D | Cav1.3 | Antagonist | 7.7 | 0.3% | Q01668 |
| CACNA1F | Cav1.4 | Antagonist | 6 | 0% | O60840 |
| KCNA1 | Kv1.1 | 4 | 0% | Q09470 | |
| KCNA2 | Kv1.2 | Pore blocker | 4.7 | 0.7% | P16389 |
| KCNA5 | Kv1.5 | 4.1 | 0.2% | P22460 | |
| KCNA7 | Kv1.7 | 4.9 | 0.5% | Q96RP8 | |
| KCNC1 | Kv3.1 | 3.9 | 1.7% | P48547 | |
| NR1I2 | Pregnane X receptor | Agonist | 0.3% | O75469 |
Broader ChEMBL bioactivity targets: 77 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Indoleamine 2,3-dioxygenase 1, Transient receptor potential cation channel subfamily A member 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Survival motor neuron protein, Fructose-bisphosphate aldolase, Prelamin-A/C, RecQ-like DNA helicase BLM.
Bioactivity
ChEMBL activities: 108 potent at pChembl ≥ 5 of 211 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| CACNA1C | 9.4 | Kd | 0.4 | nM | CHEMBL_ACT_1086672 |
| P16257 | 9.3 | IC50 | 0.5 | nM | CHEMBL_ACT_25872933 |
| CACNA1C | 9 | Ki | 1 | nM | CHEMBL_ACT_106372 |
| P15381 | 9 | IC50 | 1 | nM | CHEMBL_ACT_202265 |
| P27732 | 8.92 | Ki | 1.2 | nM | CHEMBL_ACT_360695 |
| P22002 | 8.85 | IC50 | 1.42 | nM | CHEMBL_ACT_14664858 |
| P22002 | 8.78 | IC50 | 1.65 | nM | CHEMBL_ACT_1147239 |
| P22002 | 8.7 | IC50 | 2 | nM | CHEMBL_ACT_12418277 |
| P22002 | 8.6 | IC50 | 2.53 | nM | CHEMBL_ACT_418338 |
| O35505 | 8.59 | IC50 | 2.6 | nM | CHEMBL_ACT_12405458 |
| P22002 | 8.59 | IC50 | 2.57 | nM | CHEMBL_ACT_12418273 |
| P27732 | 8.57 | IC50 | 2.7 | nM | CHEMBL_ACT_360694 |
| P15381 | 8.54 | IC50 | 2.9 | nM | CHEMBL_ACT_543323 |
| P22002 | 8.46 | Ki | 3.5 | nM | CHEMBL_ACT_338301 |
| P22002 | 8.33 | Ki | 4.65 | nM | CHEMBL_ACT_921112 |
| CACNA1F | 8 | IC50 | 10 | nM | CHEMBL_ACT_15373341 |
| P22002 | 7.92 | EC50 | 12 | nM | CHEMBL_ACT_10943203 |
| CACNA1F | 7.84 | Ki | 14.45 | nM | CHEMBL_ACT_18097434 |
| CACNA1F | 7.82 | Ki | 15 | nM | CHEMBL_ACT_18097433 |
| CACNA1C | 7.66 | IC50 | 22 | nM | CHEMBL_ACT_15373259 |
| P22002 | 7.56 | IC50 | 27.54 | nM | CHEMBL_ACT_12418264 |
| P22002 | 7.56 | IC50 | 27.5 | nM | CHEMBL_ACT_12418276 |
| CACNA1C | 7.4 | IC50 | 40 | nM | CHEMBL_ACT_29239025 |
| CYP1A2 | 7.4 | AC50 | 39.81 | nM | CHEMBL_ACT_6025154 |
| O35505 | 7.3 | IC50 | 50 | nM | CHEMBL_ACT_12479834 |
| CACNA1C | 7.3 | IC50 | 50 | nM | CHEMBL_ACT_15373257 |
| O35505 | 7.3 | IC50 | 50 | nM | CHEMBL_ACT_15373262 |
| CYP1A2 | 7.3 | AC50 | 50.12 | nM | CHEMBL_ACT_6059663 |
| CACNA1C | 7.26 | IC50 | 55 | nM | CHEMBL_ACT_15373260 |
| P22002 | 7.24 | IC50 | 57.7 | nM | CHEMBL_ACT_12418278 |
Target pathways
Aggregated over 14 target gene(s): GLRA1, GLRA3, GLRB, TRPM3, CACNA1S, CACNA1C, CACNA1D, CACNA1F, KCNA1, KCNA2, KCNA5, KCNA7, KCNC1, NR1I2.
Top Reactome pathways
24 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Neuronal System | 5 | KCNA1, KCNA2, KCNA5, KCNA7, KCNC1 |
| Potassium Channels | 5 | KCNA1, KCNA2, KCNA5, KCNA7, KCNC1 |
| Voltage gated Potassium channels | 5 | KCNA1, KCNA2, KCNA5, KCNA7, KCNC1 |
| Neurotransmitter receptors and postsynaptic signal transmission | 3 | GLRA1, GLRA3, GLRB |
| Developmental Biology | 3 | CACNA1C, CACNA1D, CACNA1S |
| NCAM signaling for neurite out-growth | 3 | CACNA1C, CACNA1D, CACNA1S |
| NCAM1 interactions | 3 | CACNA1C, CACNA1D, CACNA1S |
| Axon guidance | 3 | CACNA1C, CACNA1D, CACNA1S |
| Nervous system development | 3 | CACNA1C, CACNA1D, CACNA1S |
| Metabolism | 2 | CACNA1C, CACNA1D |
| Integration of energy metabolism | 2 | CACNA1C, CACNA1D |
| Muscle contraction | 2 | CACNA1C, KCNA5 |
| Adrenaline,noradrenaline inhibits insulin secretion | 2 | CACNA1C, CACNA1D |
| Regulation of insulin secretion | 2 | CACNA1C, CACNA1D |
| Cardiac conduction | 2 | CACNA1C, KCNA5 |
| TRP channels | 1 | TRPM3 |
| Nuclear Receptor transcription pathway | 1 | NR1I2 |
| SUMOylation of intracellular receptors | 1 | NR1I2 |
| Phase 3 - rapid repolarisation | 1 | KCNA5 |
| Phase 0 - rapid depolarisation | 1 | CACNA1C |
| Phase 2 - plateau phase | 1 | CACNA1C |
| Sensory processing of sound | 1 | CACNA1D |
| Sensory processing of sound by inner hair cells of the cochlea | 1 | CACNA1D |
| Sensory Perception | 1 | CACNA1D |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| monoatomic ion transport | 13 |
| monoatomic ion transmembrane transport | 13 |
| transmembrane transport | 10 |
| protein homooligomerization | 6 |
| regulation of membrane potential | 5 |
| calcium ion transport | 5 |
| calcium ion transmembrane transport | 5 |
| action potential | 5 |
| potassium ion transmembrane transport | 5 |
| potassium ion transport | 5 |
| muscle contraction | 4 |
| calcium ion import across plasma membrane | 4 |
| startle response | 3 |
| chloride transport | 3 |
| visual perception | 3 |
Indications & clinical
Indications
19 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hypertensive disorder | 4 | MONDO:0005044 | EFO:0000537 |
| cardiovascular disorder | 4 | MONDO:0004995 | EFO:0000319 |
| coronary vasospasm | 4 | MONDO:0005356 | EFO:0004225 |
| placenta praevia | 3 | MONDO:0005918 | EFO:0007442 |
| Raynaud disease | 3 | MONDO:0008364 | EFO:1001145 |
| myocardial ischemia | 3 | MONDO:0024644 | EFO:1001375 |
| diabetic kidney disease | 3 | MONDO:0005016 | EFO:0000401 |
| pulmonary hypertension | 3 | MONDO:0005149 | MONDO:0005149 |
| nephrolithiasis | 3 | MONDO:0008171 | EFO:0004253 |
| preeclampsia | 3 | MONDO:0005081 | EFO:0000668 |
| chronic kidney disease | 2 | MONDO:0005300 | EFO:0003884 |
| proteinuria | 2 | MONDO:0003634 | HP:0000093 |
| focal epilepsy | 2 | MONDO:0005384 | EFO:0004263 |
| anus disorder | 2 | MONDO:0002519 | EFO:0009660 |
| epilepsy | 2 | MONDO:0005027 | EFO:0000474 |
| drug dependence | 1 | MONDO:0005303 | EFO:0003890 |
| congenital adrenal hyperplasia | 1 | MONDO:0018479 | MONDO:0018479 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 95.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 28 |
| Not specified | 25 |
| PHASE3 | 16 |
| PHASE2 | 9 |
| PHASE1 | 7 |
| PHASE2/PHASE3 | 6 |
| PHASE1/PHASE2 | 3 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06915792 | PHASE4 | NOT_YET_RECRUITING | PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy |
| NCT00244530 | PHASE4 | COMPLETED | Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery |
| NCT00599898 | PHASE4 | COMPLETED | Nifedipine Compared to Atosiban for Treating Preterm Labor |
| NCT00672113 | PHASE4 | COMPLETED | Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension |
| NCT00750113 | PHASE4 | COMPLETED | Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control. |
| NCT01010048 | PHASE4 | UNKNOWN | Compare the Therapeutic Effect Treated With Tamsulosin and Progesterone After ESWL( Extra Corporeal Shock Wave Lithotripsy) in Urinary Calculus |
| NCT01167153 | PHASE4 | COMPLETED | Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients |
| NCT01830530 | PHASE4 | COMPLETED | HIGH Altitude CArdiovascular REsearch in the ANDES |
| NCT01912677 | PHASE4 | COMPLETED | Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy |
| NCT02068404 | PHASE4 | UNKNOWN | Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour |
| NCT02357615 | PHASE4 | UNKNOWN | Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure |
| NCT02438371 | PHASE4 | TERMINATED | Nifedipine or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor |
| NCT02499822 | PHASE4 | COMPLETED | REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial |
| NCT02531490 | PHASE4 | UNKNOWN | Early Vascular Adjustments During Hypertensive Pregnancy |
| NCT02583633 | PHASE4 | COMPLETED | Transdermal Nitroglycerin and Nifedipine in Preterm Labor |
| NCT02641821 | PHASE4 | UNKNOWN | Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension |
| NCT02940548 | PHASE4 | TERMINATED | Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness |
| NCT03005496 | PHASE4 | COMPLETED | The Effect of Zinc, β-carotene, and Vitamin D3 in Preterm Delivery Through Placental MyD88, TRIF, NFkB, and IL-1β |
| NCT03040752 | PHASE4 | COMPLETED | Comparative Study Between Nifedipine and Ritodrine as Maintenance Tocolytic Therapy in Preterm Labor |
| NCT03506724 | PHASE4 | COMPLETED | Response to Anti-hypertensives in Pregnant and Postpartum Patients |
| NCT03595982 | PHASE4 | TERMINATED | Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily? |
| NCT03710395 | PHASE4 | UNKNOWN | Genetic Polymorphisms of ABCG2/BCRP on the Transport of Nifedipine to Breast Milk. |
| NCT04349124 | PHASE4 | TERMINATED | Persistent Postpartum Hypertension Pilot Trial |
| NCT04392375 | PHASE4 | COMPLETED | Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor |
| NCT05139238 | PHASE4 | TERMINATED | Postpartum Hypertension Study |
| NCT05711810 | PHASE4 | COMPLETED | Medicine-induced Cardiac Hemodialysis on COVID-19 |
| NCT06859554 | PHASE4 | COMPLETED | Efficacy and Safety of GTN vs. Nifedipine in Acute Anal Fissure: A Clinical Trial |
| NCT07523295 | PHASE4 | COMPLETED | Effect of Vaginal Progesterone Treatment on Pregnancy and Newborn Outcomes in Women With Preterm Labor |
| NCT03976063 | PHASE3 | ACTIVE_NOT_RECRUITING | Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation |
| NCT04298034 | PHASE3 | ACTIVE_NOT_RECRUITING | Preeclampsia Postpartum Antihypertensive Treatment |
| NCT05551104 | PHASE3 | RECRUITING | Safest Choice of Antihypertensive Regimen for Postpartum Hypertension |
| NCT00000478 | PHASE3 | COMPLETED | Asymptomatic Cardiac Ischemia Pilot (ACIP) Study |
| NCT00000530 | PHASE3 | COMPLETED | Raynaud’s Treatment Study (RTS) |
| NCT00004266 | PHASE3 | COMPLETED | Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes |
| NCT00137501 | PHASE3 | TERMINATED | Two Dose Regimens of Nifedipine for the Management of Preterm Labor |
| NCT00519870 | PHASE3 | COMPLETED | Losartan Therapy in Pulmonary Hypertension |
| NCT00713739 | PHASE3 | UNKNOWN | Alfuzosin for Medical Expulsion Therapy of Ureteral Stones |
| NCT01314859 | PHASE3 | WITHDRAWN | Nifedipine Treatment in Preterm Labor |
| NCT01360034 | PHASE3 | UNKNOWN | Nifedipine Versus Indomethacin in the Treatment of Preterm Labour |
| NCT02132533 | PHASE3 | COMPLETED | Nifedipine for Acute Tocolysis of Preterm Labor |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 5 clinical and 25 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
391 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| FLECAINIDE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, KCNA1, KCNA5, KCNA7 |
| DILTIAZEM | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, KCNA1, KCNA5 |
| QUINIDINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, KCNA5, KCNA7 |
| SERTINDOLE | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, KCNA5, NR1I2 |
| AMIODARONE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, KCNA7 |
| LORATADINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, NR1I2 |
| NIMODIPINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, NR1I2 |
| Nisoldipine | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, NR1I2 |
| PIMOZIDE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, GLRA1 |
| RISPERIDONE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, GLRA1 |
| VERAPAMIL | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, KCNA7 |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, GLRA1 |
| BEPRIDIL | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S, NR1I2 |
| NITRENDIPINE | ChEMBL | Phase 3 | CACNA1C, CACNA1D, CACNA1F, CACNA1S, NR1I2 |
| Belzutifan | PubChem | Approved | CACNA1C, CACNA1D, CACNA1F, CACNA1S, KCNA5 |
| AMITRIPTYLINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| Ceftriaxone | ChEMBL + PubChem | Phase 4 (approved) | CACNA1D, CACNA1F, CACNA1S, NR1I2 |
| CHLORPROMAZINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| CILOSTAZOL | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| CLOZAPINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| DIAZEPAM | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| DOFETILIDE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| DONEPEZIL | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| DROPERIDOL | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| DULOXETINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| HALOPERIDOL | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| IBUTILIDE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| IMIPRAMINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| LAMIVUDINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| METHADONE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| MEXILETINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| MITOXANTRONE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| NILOTINIB | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| PAROXETINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| PHENYTOIN | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| SAQUINAVIR | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| SOLIFENACIN | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| SUNITINIB | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| THIORIDAZINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| CISAPRIDE | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| DASATINIB | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| HALOFANTRINE | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| MIBEFRADIL | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| SPARFLOXACIN | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| TACRINE | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| TERFENADINE | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| TERODILINE | ChEMBL | Phase 4 (approved) | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| AJMALINE | ChEMBL | Phase 3 | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| CIFENLINE | ChEMBL | Phase 2 | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| GALLOPAMIL | ChEMBL | Phase 2 | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| Moxifloxacin | PubChem | Approved | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| Paliperidone | PubChem | Approved | CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| AMLODIPINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, NR1I2 |
| ISRADIPINE | ChEMBL + PubChem | Phase 4 (approved) | CACNA1C, CACNA1D, NR1I2 |
| FLUSPIRILENE | ChEMBL | Phase 4 (approved) | CACNA1C, GLRA1, NR1I2 |
| Disopyramide | PubChem | Approved | CACNA1D, CACNA1F, CACNA1S |
| Linezolid | PubChem | Approved | CACNA1D, CACNA1F, CACNA1S |
| Melatonin | PubChem | Approved | CACNA1D, CACNA1F, CACNA1S |
| Metronidazole | PubChem | Approved | CACNA1D, CACNA1F, CACNA1S |
| Pemigatinib | PubChem | Approved | CACNA1D, CACNA1F, CACNA1S |
Related Atlas pages
- Genes: GLRA1, GLRA3, GLRB, TRPM3, CACNA1S, CACNA1C, CACNA1D, CACNA1F, KCNA1, KCNA2, KCNA5, KCNA7, KCNC1, NR1I2
- Diseases: hypertensive disorder, cardiovascular disorder, coronary vasospasm, placenta praevia, Raynaud disease, myocardial ischemia, diabetic kidney disease, pulmonary hypertension, nephrolithiasis, preeclampsia
- Drugs: Flecainide, Diltiazem, Quinidine, Sertindole, Amiodarone, Loratadine, Nimodipine, Nisoldipine, Pimozide, Risperidone, Verapamil, Astemizole, Bepridil, Nitrendipine, Belzutifan, Amitriptyline, Ceftriaxone, Chlorpromazine, Cilostazol, Clozapine, Diazepam, Dofetilide, Donepezil, Droperidol, Duloxetine, Haloperidol, Ibutilide, Imipramine, Lamivudine, Methadone, Mexiletine, Mitoxantrone, Nilotinib, Paroxetine, Phenytoin, Saquinavir, Solifenacin, Sunitinib, Thioridazine, Cisapride, Dasatinib, Halofantrine, Mibefradil, Sparfloxacin, Tacrine, Terfenadine, Terodiline, Ajmaline, Moxifloxacin, Paliperidone, Amlodipine, Isradipine, Fluspirilene, Disopyramide, Linezolid, Melatonin, Metronidazole, Pemigatinib